SS
OVID icon

SBI Securities’s Ovid Therapeutics OVID Stock Holding History

SBI Securities’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$239 Sell
89
-18
-17% -$46 ﹤0.01% 3272
2026
Q1 		$238 Sell
107
-82
-43% -$147 ﹤0.01% 3158
2025
Q4 		$308 Sell
189
-236
-56% -$364 ﹤0.01% 3059
2025
Q3 		$553 Sell
425
-459
-52% -$398 ﹤0.01% 2931
2025
Q2 		$292 Hold
884
– – ﹤0.01% 3188
2025
Q1 		$276 Buy
884
+800
+952% +$492 ﹤0.01% 3105
2024
Q4 		$78 Buy
+84
New +$94 ﹤0.01% 3530

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

SBI Securities's OVID Position: Q2 2026 in Review

SBI Securities reduced its Ovid Therapeutics (OVID) stake by 17% in Q2 2026, selling an estimated $46 and leaving 89 shares worth $239. The position accounts for ﹤0.01% of the portfolio, ranked #3272.

SBI Securities first reported a position in OVID in Q4 2024 and has held it in 7 quarters since. The position peaked at $553 in Q3 2025. 130 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • SBI Securities held 89 shares of Ovid Therapeutics worth $239 as of Q2 2026.
  • SBI Securities sold 18 Ovid Therapeutics shares in Q2 2026, an estimated $46.
  • Ovid Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3272 holding.
  • SBI Securities first reported a position in Ovid Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Ovid Therapeutics position peaked at $553 in Q3 2025.
  • 130 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.